Lilly's Carroll Talks Innovation, Partnering And Business Development Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Eli Lilly Senior VP-Corporate Business Development Darren Carroll weighed in on pharmaceutical innovation, biotech valuations and the rising bar for external innovation during an interview at the J.P. Morgan Healthcare conference.
You may also be interested in...
Lilly’s Venture Strategy Matures As PoC Data Catalysts Approach
As part of a new R&D investment approach, Eli Lilly has partnered with TVM Capital and HealthCare Ventures, which have raised $250 million and funded the start of eight single-molecule companies. Corporate Business Development VP Darren Carroll discussed how the company’s venture initiative has evolved during Elsevier’s Pharmaceutical Strategic Alliance conference Sept. 25.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.